---
title: "NeOnc Technologies: CEO buys $300K stock; $62M net loss driven by $45.2M non-cash charges, $13M financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283054852.md"
description: "NeOnc Technologies' CEO Amir Heshmatpour purchased approximately $300,000 in stock, reflecting management's confidence amid upcoming clinical developments. The company reported a net loss of $62 million for 2025, primarily due to $45.2 million in non-cash stock compensation and $9.6 million in listing advisory fees. Normalized cash operating expenses were about $10.1 million. Additionally, a private placement raised around $13 million to help repay debts. Key upcoming events include an FDA meeting for NEO212 and interim data for NEO100."
datetime: "2026-04-16T21:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283054852.md)
  - [en](https://longbridge.com/en/news/283054852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283054852.md)
---

# NeOnc Technologies: CEO buys $300K stock; $62M net loss driven by $45.2M non-cash charges, $13M financing

**NeOnc Technologies announced CEO Amir Heshmatpour purchased ~$300,000 of stock and provided context on 2025 results showing a $62M net loss driven largely by non‑cash and listing charges.**

**Key Highlights:**

-   Chairman & CEO bought ~ $300,000 of NeOnc stock, signaling management confidence ahead of upcoming clinical catalysts.
-   Reported 2025 net loss ~ $62M; ~$45.2M of that was non‑cash stock compensation and $9.6M listing advisory fees.
-   Normalized cash operating expenses ~ $10.1M for 2025 after excluding non‑cash and non‑recurring items.
-   Completed Q1 2026 private placement raising gross proceeds of ~ $13.0M; used partly to repay convertible debt and accrued obligations.
-   Near‑term clinical catalysts: NEO212 FDA Type B End‑of‑Phase meeting within ~4 weeks; NEO100 interim data readout expected in ~4 months.

Original SEC Filing: NEONC TECHNOLOGIES HOLDINGS, INC. \[ NTHI \] - 8-K - Apr. 16, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NTHI.US](https://longbridge.com/en/quote/NTHI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)